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Abstract
Background: Systemic biomarkers provide insights into disease pathogenesis, diagnosis, and risk stratification. Many
systemic biomarker concentrations are heritable phenotypes. Genome-wide association studies (GWAS) provide
mechanisms to investigate the genetic contributions to biomarker variability unconstrained by current knowledge of
physiological relations.
Methods: We examined the association of Affymetrix 100K GeneChip single nucleotide polymorphisms (SNPs) to 22
systemic biomarker concentrations in 4 biological domains: inflammation/oxidative stress; natriuretic peptides; liver
function; and vitamins. Related members of the Framingham Offspring cohort (n = 1012; mean age 59 ± 10 years, 51%
women) had both phenotype and genotype data (minimum-maximum per phenotype n = 507–1008). We used
Generalized Estimating Equations (GEE), Family Based Association Tests (FBAT) and variance components linkage to
relate SNPs to multivariable-adjusted biomarker residuals. Autosomal SNPs (n = 70,987) meeting the following criteria
were studied: minor allele frequency ≥ 10%, call rate ≥ 80% and Hardy-Weinberg equilibrium p ≥ 0.001.
Results: With GEE, 58 SNPs had p < 10-6: the top SNPs were rs2494250 (p = 1.00*10-14) and rs4128725 
(p = 3.68*10-12) for monocyte chemoattractant protein-1 (MCP1), and rs2794520 (p = 2.83*10-8) and rs2808629 (p =
3.19*10-8) for C-reactive protein (CRP) averaged from 3 examinations (over about 20 years). With FBAT, 11 SNPs had
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BMC Medical Genetics 2007, 8(Suppl 1):S11 http://www.biomedcentral.com/1471-2350/8/S1/S11p < 10-6: the top SNPs were the same for MCP1 (rs4128725, p = 3.28*10-8, and rs2494250, p = 3.55*10-8), and also
included B-type natriuretic peptide (rs437021, p = 1.01*10-6) and Vitamin K percent undercarboxylated osteocalcin
(rs2052028, p = 1.07*10-6). The peak LOD (logarithm of the odds) scores were for MCP1 (4.38, chromosome 1) and
CRP (3.28, chromosome 1; previously described) concentrations; of note the 1.5 support interval included the MCP1
and CRP SNPs reported above (GEE model). Previous candidate SNP associations with circulating CRP concentrations
were replicated at p < 0.05; the SNPs rs2794520 and rs2808629 are in linkage disequilibrium with previously reported
SNPs. GEE, FBAT and linkage results are posted at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007.
Conclusion: The Framingham GWAS represents a resource to describe potentially novel genetic influences on systemic
biomarker variability. The newly described associations will need to be replicated in other studies.
Background
There is intense clinical and research interest in blood and
urinary biomarkers to diagnose disease, to risk stratify
individuals for prognosis and potential intervention, and
to provide insights into disease pathogenesis [1]. Hence,
it has been proposed that biomarkers may prove useful in
the goal of developing what has been referred to as "pre-
dictive, preemptive, personalized medicine" [2].
In the present analysis, we examined biomarkers involv-
ing four biological systems: inflammation, natriuretic
peptides, hepatic function, and vitamins. Circulating
inflammatory, natriuretic peptides [3-5], hepatic function
[6,7] and vitamin [8] biomarker concentrations have been
linked to increased risk of cardiovascular disease and mor-
tality. For instance, the inflammatory marker C-reactive
protein (CRP) predicts incident stroke [9], coronary heart
disease [10-12], and all-cause mortality [13].
Because of their prognostic importance, there has been
interest in understanding the environmental and genetic
factors contributing to interindividual variability in sys-
temic biomarker concentrations. Prior reports support the
heritability of systemic biomarker concentrations reflect-
ing inflammatory processes [14,15], natriuretic peptides
activation [16], hepatic function [17,18], and vitamin
metabolism [19]. The majority of prior studies examining
the genetic contribution to biomarker concentrations
have examined genetic linkage or variation in selected
candidate genes. Although there have been some suc-
cesses with both approaches [20], the specific genes con-
tributing to variability of most circulating biomarkers are
incompletely understood. We examined the relation of
single nucleotide polymorphisms (SNPs) on the Affyme-
trix 100K chip to variation in systemic biomarker concen-
trations. The GWAS approach has the advantage that it is
not constrained by known physiologic associations.
Materials and methods
Study sample
The biomarkers were assessed in the Framingham Off-
spring sample, which is described in the Framingham
100K Overview [21]. Briefly, the Framingham Offspring
were recruited in 1971–1974 from the children (and chil-
dren's spouses) of the Framingham Original Cohort [22].
The examinations and the number of participants in
which the biomarkers were assessed vary by analyte, as
noted in Table 1.
Phenotype definitions and methods
Biomarkers were measured on morning specimens after
an overnight fast (typically 10 hours) between 7:30 and
9:00 am. EDTA and citrated blood collection tubes are
centrifuged in a refrigerated centrifuge immediately after
venipuncture. Serum blood collection tubes sit for 30
minutes after venipuncture to allow for complete clotting.
Specimens are processed immediately after centrifuga-
tion. Blood samples were centrifuged and frozen at -20°
(examination 2 through 4) and -80° (examinations 5
through 7). The measurement of the inflammatory mark-
ers is detailed in the inflammatory marker manual at the
National Center for Biotechnology Information http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007.
Inflammatory biomarkers (except CRP) were measured
in duplicate with commercially available ELISA kits: R&D
Systems (intercellular adhesion molecule-1, interleukin-
6, monocyte chemoattractant-1 [MCP1], P-selectin,
tumor necrosis factor receptor 2, high sensitivity tumor
necrosis factor-α), Bender MedSystems (CD40 ligand),
Oxis (myeloperoxidase), and BIOMEDICA (osteoprote-
gerin). High-sensitivity CRP was measured in 2002 and
2004 on examination cycle 2, 6 and 7 specimens with a
Dade Behring nephelometer; the less sensitive Hemagen
assay was used in 1998 for examination cycle 5 speci-
mens. Natriuretic peptides were measured by Shionogi
using a noncompetitive high sensitivity immunoradio-
metric assay [23]. Liver function tests were measured at
examination cycle 2 by Quest Diagnostics (previously
METPATH) with a variety of methods: γ-glutamyl ami-
notransferase was measured with spectrophotometry [7],
bilirubin was measured by the colorimetric method (Dow
Bilirubin Kit) [24,25]; alkaline phosphatase was meas-Page 2 of 12
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notransferase and alanine aminotransferase were
measured using the kinetic method with Beckman Liquid-
Stat Reagent Kit [28]. Vitamin K status was measured as
phylloquinone concentrations with reverse phase high-
performance liquid chromatography [29], and percentage
of undercarboxylated osteocalcin was measured by radio-
immunoassay [30,31], Vitamin D status was measured as
25(OH)D concentrations by using RIA (DiaSorin,
Stillwater MN).
Plasma samples were used for natriuretic peptides, vita-
min K phylloquinone, vitamin D, and some inflamma-
tory markers including CD40 ligand, osteoprotegerin, P-
selectin, tumor necrosis factor receptor 2, and tumor
necrosis factor-α. Serum samples were analyzed for liver
Table 1: Types of traits phenotype master trait table, exam cycle, numbers of participants in family plates with phenotype
Phenotype Acronym Trait N = 27* Subject N Offspring Exam Adjustment* Multivariable model
Inflammation/Oxidative Stress
CD40 Ligand, serum & plasma CD40L 2 998 7 Age, sex, smoking, systolic and 
diastolic blood pressure, hypertension 
treatment, body mass index, waist 
circumference, Total/HDL cholesterol, 
triglyceride, lipid lowering medication, 
glucose, diabetes, aspirin, hormone 
replacement therapy and prevalent 
cardiovascular disease
C-reactive protein CRP 5 980–1008 2, 5, 6, 7; Average: 2, 6, 7
Intercellular adhesion molecule-1 ICAM1 1 1006 7
Interleukin-6 IL6 1 1006
Urinary isoprostanes/creatinine IsoCrUrine 1 828
Monocyte chemoattractant protein-1 MCP1 1 989
Myeloperoxidase MPO 1 974
Osteoprotegerin OPG 1 1005
P-selectin Pselectin 1 1007
Tumor necrosis factor alpha TNFA 1 753
Tumor necrosis factor receptor-2 TNFRII 1 980
Natriuretic Peptides
N-terminal pro-atrial natriuretic peptide ANP 1 938 6 Age, sex, BMI, SBP, HTN Rx, LDL 
Total/HDL, diabetes, LV mass, LA size, 
CVD
B-type natriuretic peptide BNP 1 938
Liver Function
Bilirubin Bili 1 910 2 Age, sex, BMI, HDL, HTN, diabetes, 
serum total protein, alcohol intake, 
TG, & smoking
Aspartate aminotransferase ** AST 1 904
Alanine aminotransferase ALT 1 904
Alkaline phosphatase AlkPhos 1 904
Gamma-glutamyl transferase GGT 1 896
Vitamins
Vitamin K plasma phylloquinone VitKPhylloq 1 518 6/7† Age, sex, SBP, DBP, BMI, waist, total/
HDL, smoking, glucose, TG, diabetes, 
HTN Rx, lipid lowering Rx, hormone 
replacement Rx, asthma Rx, alcohol 
use, prevalent CVD
Vitamin K percentage of undercarboxylated osteocalcin VitKPucOC 1 504
Vitamin D plasma 25(OH)-D VitD25OH 1 517
*Each trait had 2 adjustment schemes web posted: age- and sex-adjusted, and multivariable-adjusted at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007. GEE and FBAT traits are web displayed pha001115 through pha001218; Linkage traits are located from pha002301 through pha002352. In the 
present manuscript we examine the multivariable-adjusted trait, which we count as 1 trait. Note: biomarkers were natural log transformed due to skewed 
distribution; **normalized deviates. †Vitamin measurements straddled exams 6 & 7, covariates from same exam biomarker assayed. SBP, DBP = systolic and diastolic blood 
pressure, HTN Rx = hypertension treatment, BMI = body mass index, TC/HDL = total/high density lipoprotein cholesterol; TG = triglyceride, HRT = hormone replacement 
therapy, Rx = medication therapy, CVD = cardiovascular disease; LDL = low density lipoprotein; LV mass = left ventricular mass; LA size = left atrial size; Atrial natriuretic 
peptide = N-terminal pro-atrial natriuretic peptide.Page 3 of 12
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and other inflammatory markers including CRP, inter-
leukin-6, soluble intracellular adhesion molecule-1,
MCP1, and myeloperoxidase concentrations. The repro-
ducibility of the biomarkers was good; the intra-assay
coefficients of variation were CD40 ligand 4.4%, inter-
leukin-6 3.1%, intercellular adhesion molecule-1 3.1%,
MCP1 4.1%, myeloperoxidase 3.0%, osteoprotegerin
3.7%, P-selectin 3.0%, tumor necrosis factor-α 8.8%, and
tumor necrosis factor receptor-2 2.3%; the inter-assay
coefficients of variation were brain natriuretic peptide
12.2%, n-terminal-atrial natriuretic peptide 12.7%. The
Kappa statistic for 146 CRP samples run in duplicate was
0.95 [32]. Coefficients of variation for aspartate ami-
notransferase and alanine aminotransferase, respectively,
were 10.7 and 8.3%. The coefficients of variation for low
and high Vitamin K plasma phylloquinone concentra-
tions were 15.2 and 10.9% respectively on control speci-
mens. For low, medium and high osteocalcin
concentrations used to determine Vitamin K percentage of
undercarboxylated osteocalcin, the coefficients of varia-
tion were 22.3, 12.8, and 7.8%, respectively. For Vitamin
D, the coefficients of variation were 8.5% and 13.2%,
respectively.
Genotyping methods
Details of the genotyping methods are available in the
Framingham Heart Study 100K Overview [21]. Framing-
ham staff extracted genomic DNA with a Qiagen Blood
and Cell Culture Maxi Kit from immortalized lymphob-
lasts. Briefly, SNPs on the Affymetrix 100K chip were gen-
otyped (n = 112,990 autosomal SNPs) in a sample of
family members of the Original and Offspring cohorts of
the Framingham Heart Study [33]. SNPs were excluded for
the following reasons: minor allele frequency <10% n =
38062; call rate <80% n = 2346; Hardy-Weinberg equilib-
rium p-value < 0.001 n = 1595, leaving 70,987 SNPs avail-
able for analysis.
Statistical analysis methods
We created standardized multivariable-adjusted natural
log transformed biomarker residuals adjusted for the cov-
ariates listed in Table 1. The CRP average residuals were
constructed as follows: (1) create age- and sex-adjusted or
multivariable-adjusted residual at each of exams 2, 6 and
7; (2) take average of the residuals across exams; (3) the
residual was excluded if there were not at least 2 exams for
its calculation. In some instances we performed addi-
tional transformation (e.g. Winsorized models). Tobit
models were used to generate residuals for the natriuretic
peptides, because 2% of N-ANP levels and 30% of BNP
levels were below the respective assay detection limits.
Association and linkage results examining age- and sex-
adjusted residuals are posted at the web site. As described
in the Overview [21], we examined generalized estimating
equations (GEE) and family based association testing
(FBAT), assuming an additive genetic effect, to account for
correlation among related individuals within nuclear fam-
ilies. We also used Merlin software [34] (splitting the larg-
est families) to compute exact identity by descent linkage,
with variance component analysis in SOLAR using 11,200
SNPs and short tandem repeats [35]. Traits with extreme
values, as defined by 4 standard deviations away from the
mean, were Winsorized at 4.0 in secondary linkage analy-
ses to determine the sensitivity of the logarithm of the
odds (LOD) score to the presence of outlier values.
Results
Twenty-two biomarker traits (plus 4 additional CRP
traits) were analyzed in 1012 Offspring participants, on
log-transformed multivariable-adjusted residuals as out-
lined in Table 1 (minimum-maximum per phenotype n =
507–1008). The phenotypes were collected at various
Framingham Offspring examinations from cycles 2 to 7.
At examination cycles 2 and 7 the mean age of the partic-
ipants with both phenotype and genotype data was 41 ±
10 and 59 ± 10 years, and 51.2% and 51.1% were women,
respectively. For details of biomarker phenotype-genotype
association refer to http://www.ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?id=phs000007.
There were 58 SNPs associated with biomarker concentra-
tions with a p < 10-6 by GEE. The 25 most statistically sig-
nificant GEE associations sorted by p-value, listed with
their corresponding FBAT p-value are shown in Table 2a.
MCP1 concentrations were associated with rs2494250 (p
= 1*10-14) and rs4128725 (p = 3.68*10-12), both on chro-
mosome 1, near the FCER1A and the OR10J1 genes,
respectively. CRP concentrations averaged over 3 exami-
nations (about 20 years) were associated with rs2794520
(p = 2.83*10-8) and rs2808629 (p = 3.19*10-8).
We estimated the amount of variability in biomarker con-
centrations explained by the 4 most statistically signifi-
cant SNPs in the GEE model using a pseudo measure of R2
based on log-likelihood estimates [36]. The two most sta-
tistically significant GEE SNPs explained about 7% and
4% of the variability in MCP1 concentrations (R2 = 0.070
for rs2494250 and R2 = 0.043 for rs4128725); for CRP
concentrations averaged over examinations 2, 6, and 7 the
two most statistically significant GEE SNPs explained
2.3% of the variability [R2 = 0.023 for rs2794520 and
rs2808629) [36]. We also examined the linkage disequi-
librium between the most statistically significant GEE
SNPs: rs2494250 and rs4128725 had a D' = 0.724 and an
r2 = 0.196, whereas rs2794520 and rs2808629 served as
perfect proxies for each other (D' = 1; r2 = 1).
With FBAT, 11 SNPs were associated with biomarker con-
centrations with a p < 10-6. The two most statistically sig-Page 4 of 12
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2a. Top 25 associations with biomarkers based on the lowest p value of the GEE test
Trait SNP rs ID* Chr Physical location (bp) GEE P-value FBAT P-value IN/NEAR gene
Monocyte chemoattractant protein-1 rs2494250 1 156091324 1.0*10-14 3.5*10-8 FCER1A, OR10J3
Monocyte chemoattractant protein-1 rs4128725 1 156219032 3.7*10-12 3.3*10-8 OR10J1
C-reactive protein average exams 2,6,7 rs2794520 1 156491889 2.8*10-8 4.3*10-5 CRP
C-reactive protein average exams 2,6,7 rs2808629 1 156489869 3.2*10-8 4.8*10-5 CRP
C-reactive protein exam 6 rs2794520 1 156491889 1.3*10-7 3.9*10-4 CRP
C-reactive protein exam 6 rs2808629 1 156489869 1.4*10-7 4.3*10-4 CRP
Tumor necrosis factor alpha rs7552393 1 83966572 5.1*10-7 0.63
C-reactive protein exam 6 rs746961 19 35791730 7.5*10-7 0.03 ZNF536
Bilirubin rs17532515 4 141745043 1.0*10-6 9.2*10-6 CLGN, ELMOD2
Alanine aminotransferase rs1998303 9 82644535 1.1*10-6 0.005
Monocyte chemoattractant protein-1 rs10489849 1 156009838 1.1*10-6 0.10 IGSF4B
Alkaline phosphatase rs10518765 15 52467924 1.1*10-6 1.7*10-4
Vitamin K plasma phylloquinone rs2387326 10 129823446 1.1*10-6 0.02 PTPRE, MKI67
C-reactive protein average exams 2,6,7 rs1119582 5 125270919 1.2*10-6 4.2*10-4
Vitamin D plasma 25(OH)-D rs10485165 6 89169536 1.4*10-6 0.003
Atrial natriuretic peptide exam 6 rs1417352 6 107005919 1.8*10-6 0.009
C-reactive protein exam 2 rs583012 10 54964880 1.9*10-6 0.09
Atrial natriuretic peptide exam 6 rs1486139 7 46048968 2.0*10-6 0.04
Atrial natriuretic peptide exam 6 rs1486140 7 46048877 2.2*10-6 0.06
Alanine aminotransferase exam 2 rs10492681 13 39705483 2.2*10-6 9.9*10-5
Vitamin D plasma 25(OH)-D rs10507577 13 52866092 2.6*10-6 0.004
Atrial natriuretic peptide exam 6 rs1079596 11 112801829 2.6*10-6 0.03 DRD2
Monocyte chemoattractant protein-1 rs1474747 1 155961586 2.8*10-6 8.7*10-4 IGSF4B
CD40 Ligand serum rs7778619 7 9923216 3.0*10-6 0.19
CD40 Ligand serum rs8005745 14 76473583 3.5*10-6 0.01
2b. Top 25 associations with biomarkers based on the lowest p value of the FBAT test
Trait SNP rs ID* Chr Physical location (bp) GEE P-value FBAT P-value IN/NEAR gene
Monocyte chemoattractant protein-1 rs4128725 1 156219032 3.7*10-12 3.3*10-8 OR10J1
Monocyte chemoattractant protein-1 rs2494250 1 156091324 1.0*10-14 3.5*10-8 FCER1A, OR10J3
B-type natriuretic peptide rs437021 1 61450291 1.5*10-4 1.0*10-6 NFIA
Vitamin K % undercarboxylated 
osteocalcin
rs2052028 7 15789103 5.2*10-6 1.1*10-6
CD40 Ligand plasma rs2372184 3 65673194 0.003 2.5*10-6 MAGI1
Urinary isoprostanes/creatinine rs717145 20 15826091 0.003 5.0*10-6 C20orf133
CD40 Ligand serum rs4664604 2 153398916 0.01 8.4*10-6 ARL6IP6
CD40 Ligand serum rs9288125 2 153348619 0.01 9.1*10-6 FMNL2, ARL6IP6
C-reactive protein exam 7 rs1363258 5 103297593 0.02 9.2*10-6Page 5 of 12
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Osteoprotegerin rs496269 6 79457094 0.03 9.4*10-6
C-reactive protein average 2,6,7 rs1363258 5 103297593 0.009 1.3*10-5
CD40 Ligand serum rs303939 13 71269472 0.008 1.3*10-5 DACH1
Myeloperoxidase rs10501981 11 100880825 1.1*10-5 1.4*10-5 TRPC6
Urinary isoprostanes/creatinine rs1461549 14 24782140 0.26 1.5*10-5
Tumor necrosis factor alpha rs2353803 7 11060282 0.03 1.5*10-5
Intercellular adhesion molecule-1 rs3849944 9 27550594 5.3*10-6 1.5*10-5 C9orf72
CD40 Ligand serum rs1986743 2 153412407 0.01 1.6*10-5 ARL6IP6
Gamma-glutamyl transferase rs962976 12 67006894 0.002 1.6*10-5 MDM1
C-reactive protein average 2,6,7 rs2421608 2 117013763 0.02 1.8*10-5
C-reactive protein exam 2 rs642245 11 86067184 0.03 1.9*10-5 ME3
Tumor necrosis factor receptor-2 rs248328 5 179309691 0.59 1.9*10-5 TBC1D9B, 
RNF130
C-reactive protein exam 7 rs2390582 1 90655928 0.07 2.0*10-5
Osteoprotegerin rs9352609 6 79442188 0.04 2.0*10-5
Intercellular adhesion molecule-1 rs744511 14 39166736 3.2*10-4 2.1*10-5
2c. Magnitude and Location of Peak LOD scores > 2.5 for regions in the Biomarker Phenotype Group
Trait Exam Chr Physical location (bp) Maximum 
LOD
LOD-1.5 
Interval
LOD+1.5 
Interval
Maximum LOD 
WIN*
Monocyte chemoattractant protein-1 7 1 159093573 4.96 154908901 159751221 4.38
Monocyte chemoattractant protein-1 7 10 129553148 4.03 128294406 130084334 3.23
C-reactive protein 5 1 154745847 3.53 153213133 156567571 3.28
Monocyte chemoattractant protein-1 7 17 13630703 3.33 10874193 16776778 2.54
Intercellular adhesion molecule-1 7 1 203535232 2.95 202207846 215367881 2.93
Monocyte chemoattractant protein-1 7 7 92544810 2.94 88727093 105546050 2.01
Tumor necrosis factor receptor 2 7 1 54001041 2.92 43070922 60590679 2.95
Gamma-glutamyl transferase 2 3 26424584 2.89 24621158 27418642 2.96
B-type natriuretic peptide 6 12 4140574 2.77 132045 8137669 No outliers
Gamma-glutamyl transferase 2 10 129553148 2.67 120112006 132560638 2.79
Vitamin D plasma 25(OH)-D 6/7 8 140624328 2.67 138952328 146039126 2.68
B-type natriuretic peptide 6 19 34016706 2.59 13425865 43186344 No outliers
Myeloperoxidase 7 19 11295505 2.56 3026853 16489850 2.56
Alkaline phosphatase 2 6 170538204 WIN 162441307 170788550 2.55
Osteoprotegerin 7 13 75274475 2.52 71928655 81228082 2.95
bp = base pair; Chr = chromosome; WIN = Winsorized.
dbSNP positions are from NCBI Build 35 (hg17);
LD between rs2494250 and rs4128725 (top MCP1 SNPs): D' = 0.724 and r squared = 0.196.
LD between rs2794520 and rs2808629 (top CRP SNPs): D' = 1.0 and r squared = 1.0.
*Winsorized LOD scores were run for this manuscript, and are not displayed on the web.
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with GEE: MCP1 concentrations were significantly associ-
ated with rs4128725, p = 3.28*10-8, and rs2494250, p =
3.55*10-8 (Table 2b). In addition, B-type natriuretic pep-
tide (rs437021, p = 1.01*10-6) and Vitamin K% undercar-
boxylated osteocalcin (rs2052028, p = 1.07*10-6) also
were nominally statistically significantly associated.
In Table 2c we list the magnitude and location of LOD
scores > 2.5 observed for the circulating biomarker traits.
Because we were concerned that some of the LOD scores
might be inflated by individuals with extreme marker con-
centrations, we reanalyzed the LOD scores on Winsorized
residuals. The peak Winsorized LOD scores observed were
for the biomarkers MCP1 (4.38, chromosome 1), and
CRP (3.23, chromosome 10; 3.28, chromosome 1). Of
note the 1.5 LOD support intervals for the linkage peaks
on chromosome 1 included the SNPs significantly associ-
ated with MCP1 and CRP reported above (GEE model).
In an effort to potentially uncover genetic pleiotropy we
display in Table 3 two ways to synthesize findings across
phenotypes. We examined 3 correlated inflammatory
biomarker phenotypes, interleukin-6, CRP and fibrino-
gen, and report SNPs that were significantly associated
with all 3 phenotypes by GEE or FBAT at p < 0.01 (Table
3a). We also examined phenotypes within a specific
biomarker category including CRP over multiple exami-
nations, liver function tests and vitamin concentrations
(nutrients involved in bone health [37,38]), and display
in Table 3b SNPs significant by either FBAT or GEE at a p
< 0.01 for all of the phenotypes in a given phenotype clus-
ter.
In Table 4 we compared our data with previously reported
phenotype-genotype associations in the published litera-
ture on systemic biomarker concentrations: bilirubin con-
centrations (TA repeat in UGT1A1) [39,40]; CRP (CRP)
[20,32,41-50], intercellular adhesion molecule-1
(ICAM1) [51-54], interleukin-6 (IL6) [55-62], and MCP1
Table 3: Combined phenotypes
Trait SNP rs ID Chr Physical location
(bp)
GEE P-value FBAT P-value IN/NEAR gene
3a. SNPs significant for 3 correlated phenotypes at exam 7 by either GEE or FBAT at p < 0.01
Interleukin-6, C-reactive protein and Fibrinogen rs10511884 9 31668988 5.7*10-5 0.0065
rs1887027 10 6153788 2.6*10-4 0.19 IL2RA, RBM17
rs2831617 21 28481515 6.2*10-4 0.0027
rs2831620 21 28481869 6.4*10-4 0.0022
rs2831618 21 28481749 6.4*10-4 0.0020
rs2044401 9 31659518 6.6*10-4 0.12
rs1457590 3 21530978 0.0019 0.16 ZNF659
rs6848323 4 113286305 0.0022 0.14
rs3110134 8 60260538 0.0025 0.12
rs2016740 4 113238018 0.0039 0.17
rs719006 15 59210481 0.0044 0.76 RORA
rs877936 4 113238472 0.0055 0.31
rs1436136 4 113421130 0.0062 0.039
rs1436336 3 106156256 0.0067 0.0040
rs698270 3 137592210 0.0086 0.020 STAG1
rs847428 7 16803192 0.019 0.025
rs2359763 3 23424931 0.024 0.0025
rs7969455 12 7757402 0.059 0.0015 DPPA3
rs10503717 8 22634817 0.06 0.0028
rs4899940 14 87623621 0.11 0.0019
3b. Combined phenotypes within a specific biological domain
C-reactive protein: exams 2, 5, 6, 7 rs2808629 1 156489869 6.9*10-5 4.7*10-4 NFIA, CRP
rs2794520 1 156491889 6.1*10-5 4.85*10-4 FCER1A, CRP
rs6563212 13 35380415 7.3*10-4 0.30 DCAMKL1
rs11626844 14 72413330 5.1*10-3 0.17 OR10J1, DPF3
rs9319160 13 84918646 0.002 0.09
rs910232 1 17143820 0.002 0.01 MAGI1, PADI2
Liver function: Alkaline phosphatase; AST; ALT; GGT rs4911146 20 32103708 0.01 8.4*10-6 ARL6IP6, RALY
rs953402 3 5986639 0.01 9.1*10-6 FMNL2
Vitamin D, Vitamin K phylloquinone & Vitamin K % 
undercarboxylated osteocalcin
rs1376544 4 180293700 0.02 9.2*10-6
Chr = chromosome;
For a given SNP, all of the phenotypes either FBAT or GEE significant if FBAT < 0.01 for particular SNP;
P-values = the geometric mean of the p-value for all traits within the biomarker clusterPage 7 of 12
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no SNPs within 60 KB of the ICAM1 gene on the Affyme-
trix 100K chip. There was no association between
bilirubin concentrations and 1 SNP within 30 kb
(rs741159) + 2 more SNPs within 50 kb (rs726017 and
rs6752792) of a previously reported TA repeat in
UGT1A1. Additionally, there was no association between
interleukin-6 concentrations and SNPs in the IL6 region
despite one SNP in high LD (linkage disequilibrium; r2 =
0.819) with the previously reported rs1800795 (-174G/C)
SNP. Similarly, we did not observe an association between
MCP1 concentrations and SNPs in the CCL2 region,
despite one SNP with a high r2 (0.956) with the SNP pre-
viously reported in the literature. For CRP concentrations,
we had 2 SNPs in perfect LD with rs1205, and we
observed strong evidence for replication. However, it
should be noted that this association has been previously
reported by Framingham investigators in unrelated partic-
ipants [32]. Similarly, rs431568, which is in high LD (r2 =
0.83) with 2 previously associated SNPs (rs3116653 and
rs1417938), was highly associated with many of the CRP
phenotypes.
Discussion
In collaboration with NCBI we have web-posted our unfil-
tered biomarker-genotype associations and linkage results
to provide a resource to investigators seeking to under-
stand and replicate their biomarker-genotype associa-
tions. We submit that the findings of highest priority for
follow-up are associations that were detected by several
statistical approaches. MCP1 was associated with 2 SNPs
on chromosome 1 (rs4128725 and rs2494250) with p-
values in the 10-8 by FBAT, ≤ 10-12 by GEE. Acknowledging
that linkage is less powerful and accurate, we note that the
1.5 support interval for the MCP1 linkage peak (Winso-
rized maximum LOD 4.38) on chromosome 1 supports
the GEE and FBAT analyses. Findings for CRP (chromo-
some 1), brain natriuretic peptide (chromosome 1) and
Vitamin K % undercarboxylated osteocalcin (Chromo-
some 7) are also of potential priority for follow-up. We
acknowledge that the ultimate validation of our findings
will require replication in other cohorts and functional
studies.
A fundamental challenge of GWAS tests is sorting through
associations and prioritizing SNPs for follow-up. In the
absence of external replication, one approach to synthe-
sizing findings is to examine associations across similar
biological domains, which may capture pleiotropy. We
presented the exploratory analyses in Tables 3a and 3b,
but reiterate that the findings will need to be examined in
other cohorts.
Do the findings represent true positive genetic 
associations?
It is notable that some of the associations with the strong-
est statistical support were for associations between a gene
and its protein product (e.g. CRP gene and CRP concentra-
tion). Cis-acting regulatory variants have been shown to
influence mRNA and protein levels for many genes [65].
Studies involving additional biomarker phenotypes and
variants (e.g. Affymetrix 500 K Chip) should clarify
whether cis- or trans-acting regulatory variants explain the
greatest proportion of phenotypic variation.
With GWAS, which typically test for the association of
1000s of SNPs with multiple traits, it is difficult for any
specific association to achieve genome wide significance.
For instance, a strict Bonferroni correction for the 30 traits
tested in the present study with both age/sex- and multi-
variable-adjusted models and 2 statistical methods (0.05/
(70,987*30*2*2) would require a p = 5.9 × 10-9. We sub-
mit that the most significant association in the selected
biomarker group, the FCER1A rs2494250 SNP with MCP1
concentrations achieved genome-wide significance with a
GEE p = 1.0*10-14 and a FBAT p = 3.5*10-8. It should be
noted that rs2494250 and rs4128725 are in modest link-
age disequilibrium (D' = 0.724 and r squared = 0.196)
and hence, may be serving as proxies for the same causal
SNP.
Several human and experimental studies suggest that the
association between FCER1A and MCP1 concentrations is
biologically plausible. FCER1A codes for the high affinity
Fc receptor fragment for IgE. In vitro experiments with rat
mast cells demonstrated that if aggregated the high affin-
ity receptor for IgE (FcεRI) increased gene transcription
and secretion of MCP1 [66]. Similarly, in mice mast cells
if the FcεRI was occupied by small amounts IgE/antigen,
MCP1 mRNA increased significantly [67]. In humans IgE
and MCP1 concentrations are both increased in occupa-
tional asthma [68,69]. Similar to the animal data, human
mast cells exposed to anti-IgE antibody or to IgE released
MCP1 [70-72].
Comparison with prior literature
Our efforts to compare our findings with associations pre-
viously reported in the literature underscore some of the
challenges in genetic association studies. The ICAM1 gene
did not have any markers within 60 kb on the Affymetrix
100K chip. Of the 4 genes that did have SNPs in the
marker genomic region coding, only the CRP association
was replicated in our cohort; however as noted above we
[32], as well as others [20], have previously reported this
association. For bilirubin concentrations we previously
reported significant linkage to chromosome 2q telomere
[39] and a significant association to a TA repeat in
UGT1A1, under this linkage peak [40] in FraminghamPage 8 of 12
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between bilirubin concentrations and the 3 SNP within
60 kb of UGT1A1. The previously reported interleukin-6-
IL6 and the MCP1-CCL2 associations were not replicated.
Of note, our group previously reported that rs1024611 [in
CCL2] was associated with MCP1 concentrations in unre-
lated participants [63]; the association was nowhere close
to significant in the present report (FBAT p = 0.78; GEE p
= 0.35) Possible explanations of the failure to confirm the
previously reported Framingham study MCP1-CCL2 asso-
ciation may stem from the current report having a smaller
sample size (n = 989), using different genetic markers, and
being conducted with an additive genetic model in related
participants, as opposed to the prior study using unrelated
participants (n = 1602) with recessive and dominant
models. In a recent meta-analysis of phenotype-genotype
association studies, only about one third (8 of 25) of the
associations examined were replicated [73]. There are
many plausible explanations why we did not replicate
previously reported phenotype-genotype associations.
Previous reports could represent false positive findings, or
the present and prior study cohorts may differ on key fac-
tors, which may modify the phenotype-genotype associa-
tions, or our lack of replication may represent a false
negative report because of inadequate statistical power
[73,74].
Strengths and limitations
The strengths of the present study include a comprehen-
sively characterized community-based cohort, with
biomarker phenotypes routinely assessed with careful
attention to quality control. However, the cohort was
largely middle-aged to elderly, and white of European
descent, so the findings may not be generalizable to indi-
viduals who are younger or of other ethnicity/racial
descent. DNA was collected at the 5th and 6th examina-
tions, which may have introduced a survival bias. In addi-
tion, our study was susceptible to false negative findings
because of the moderate size of the cohort; we lacked
power to detect modest associations. Conversely, similar
to most GWAS, the reported associations and linkage may
represent false positive findings from multiple statistical
testing.
Table 4: Comparison with the prior literature
Gene rs number 
previous reports
# Affy SNPs 
within 60 kb
rs ID Affy 
SNPs
Chr D' r2 Distance 
Associated SNP
MAF FBAT p-
value
GEE p-value
IL6 rs1800795
= -174G/C
7 rs6461667 7 1 0.82 30098 0.36 0.09 0.66
MCP1 rs1024611 13 rs10491109 17 1 0.04 30762 0.15 0.048 0.13
rs1080327 1 0.96 11878 0.25 0.78 0.35
rs1860181 0.92 0.27 37799 0.45 0.04 0.11
rs1860182 0.92 0.27 37649 0.45 0.046 0.11
rs3815341 1 0.02 34637 0.05 0.001 0.50
CRP average 2,6,7 rs1205 37 rs1446959 1 0.56 0.12 75429 0.39 0.86 0.002
rs1891187 0.39 0.05 53180 0.33 0.30 0.02
rs2808629 1 1 5437 0.34 4.8*105 3.2*10-8
rs2794520 1 1 3417 0.34 4.3*10-5 2.8*10-8
rs4131568 0.63 0.12 39823 0.30 0.004 0.001
rs1417938 rs1446959 0.5 0.16 77382 0.39 0.86 0.002
rs1891187 0.29 0.07 55133 0.33 0.30 0.02
rs2808629 1 0.25 7390 0.34 4.8*10-5 3.2*10-8
rs2794520 1 0.25 5370 0.34 4.3*10-5 2.8*10-8
rs4131568 1 0.83 37870 0.30 0.004 0.001
rs1446959 0.66 0.03 72832 0.39 0.86 0.002
rs3093077 rs1891187 0.47 0.02 50583 0.33 0.30 0.02
rs2808629 1 0.03 2840 0.34 4.8*10-5 3.2*10-8
rs2794520 1 0.03 820 0.34 4.3*10-5 2.8*10-8
rs4131568 1 0.03 42420 0.30 0.004 0.001
rs1446959 0.51 0.17 90106 0.39 0.86 0.002
rs3116653 rs1891187 0.31 0.08 67857 0.33 0.30 0.02
rs2808629 1 0.25 20114 0.34 4.8*10-5 3.2*10-8
rs2794520 1 0.25 18094 0.34 4.3*10-5 2.8*10-8
rs4131568 1 0.83 25146 0.30 0.004 0.001
Displayed are SNPs that are either in the highest LD (r2) with previously reported SNPs or that have an FBAT or GEE p-value < 0.05.
For bilirubin concentrations in Framingham study unrelated participants we previously reported significant linkage to chromosome 2q telomere 
[39] and a significant association to a TA repeat UGT1A1, there were no association between bilirubin concentrations and 1 SNP within 30 kb 
(rs741159) + 2 more SNPs within 50 kb (rs726017 and rs6752792). The previously reported UGT1A1 variant is not a SNP and therefore not in 
HapMap; we have no LD information and cannot assess whether the association previous reported is also present in the current sample. ICAM1 on 
chromosome 19 has 3 reported SNPs in literature (rs1799969, rs5491, rs5498), but there were no Affymetrix SNPs within 60 KB of the gene.
CCL2 [Other associated SNPs: rs2857654, rs1024610, rs2857657 are NOT in HapMap, so no LD information was available.
CRP 2 SNPs are in perfect LD with rs1205. The previously reported triallelic SNP rs3091244 is not in HapMap. CRP association was previously 
reported in Framingham unrelated participants [32].Page 9 of 12
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The Framingham GWAS and the web posting of the unfil-
tered results represent a unique resource to discover
potentially novel genetic influences on systemic biomar-
ker variability. We acknowledge that the newly described
associations will need to be replicated in other studies.
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